4887.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:15):

Stats
Today's Volume	140 000
Average Volume	255 790
Market Cap	260.50B
EPS	¥0 ( 2024-02-13 )
Next earnings date	( ¥59.41 ) 2024-05-08
Last Dividend	¥65.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	19.74
ATR14	¥3.53 (0.06%)

Volume Correlation

Long: -0.09 (neutral)

Short: -0.12 (neutral)

Signal:(32.223) Neutral

Sawai Group Holdings Co., Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sawai Group Holdings Co., Correlation - Currency/Commodity

0.40
( neutral )

0.23
( neutral )

-0.17
( neutral )

0.10
( neutral )

-0.64
( weak negative )

-0.59
( weak negative )

Sawai Group Holdings Co., Financials

Annual	2022
Revenue:	¥200.34B
Gross Profit:	¥62.63B (31.26 %)
EPS:	¥289.26

Q3	2023
Revenue:	¥48.66B
Gross Profit:	¥14.72B (30.26 %)
EPS:	¥115.45

Q2	2023
Revenue:	¥53.80B
Gross Profit:	¥17.10B (31.78 %)
EPS:	¥112.46

Q1	2023
Revenue:	¥52.99B
Gross Profit:	¥16.16B (30.49 %)
EPS:	¥80.34

Financial Reports:

No articles found.

Sawai Group Holdings Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥65.00 (N/A)	¥0 (N/A)	¥65.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sawai Group Holdings Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.15 - good (91.49%) | Divividend Growth Potential Score: 4.59 - Stable (8.26%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥65.00	2021-09-29
Last Dividend	¥65.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	¥260.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.11	--
Div. Sustainability Score	9.15
Div.Growth Potential Score	4.59
Div. Directional Score	6.87	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.11

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8544.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7868.T	Ex Dividend Junior	2023-09-28	Sporadic	0.00%
7012.T	No Dividend Player	2023-09-28	Annually	0.00%
6361.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
5232.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4323.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
3488.T	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
2726.T	Ex Dividend Junior	2024-02-28	Annually	0.00%
9616.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8155.T	Ex Dividend Knight	2023-05-30	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0749	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0392	1.200	8.69	10.00	[0 - 0.3]
returnOnEquityTTM	0.0735	1.500	-0.294	-0.441	[0.1 - 1]
payoutRatioTTM	0.372	-1.000	6.28	-6.28	[0 - 1]
currentRatioTTM	2.18	0.800	4.09	3.27	[1 - 3]
quickRatioTTM	0.782	0.800	-0.108	-0.0867	[0.8 - 2.5]
cashRatioTTM	0.254	1.500	9.70	10.00	[0.2 - 2]
debtRatioTTM	0.229	-1.500	6.19	-9.28	[0 - 0.6]
interestCoverageTTM	40.11	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.425	-1.500	8.30	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.305	1.000	8.25	8.25	[0.2 - 0.8]
operatingProfitMarginTTM	0.0968	1.000	-0.0640	-0.0640	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.524	0.800	9.84	7.87	[0.5 - 2]
Total Score				9.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.18	1.000	8.37	0	[1 - 100]
returnOnEquityTTM	0.0735	2.50	-0.189	-0.441	[0.1 - 1.5]
freeCashFlowPerShareTTM	-35.66	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	2.16	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	544.46	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.372	1.500	6.28	-6.28	[0 - 1]
pegRatioTTM	1.104	1.500	5.98	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.117	1.000	9.59	0	[0.1 - 0.5]
Total Score				4.59

Sawai Group Holdings Co.,

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.